medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2021, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2021; 41 (4)

Evaluation of renal transplantation recipients those who do not use steroid with panel reactive antibody and donor specific antibody

Tanrısev M, Kılıcaslan AT, Colak H, Yılmaz B, Ersan S, Alp A, Tugmen C, Sert I, Engin SB

Language: English
References: 21
Page: 275-281
PDF size: 254.05 Kb.


ABSTRACT

Background: Steroids are the mainstream drugs of immunosuppressive regimen in renal transplantation. They are successfully used on induction, maintenance and rejection treatment. Due to complications caused by steroids, treatments are switched to immunosuppressive agents. Graft dysfunction risk caused by reduced total immunosuppression disturbs clinicians very often. We documented the differences among patients by means of clinical presentation and PRA/DSA levels between patients who are using steroids and patients that were prescribed for steroid-free regimen. Methods: 82 individuals who did not use steroid and 52 patients on steroid treatment were included with similar rates of age, sex, primary renal disease, dialysis type, posttransplant follow-up duration and donor type. Pre and posttransplant PRA, DSA levels, posttransplant and current graft function and comorbidities were evaluated. Results: Individuals who do not use steroids were found to have a lower posttransplant creatinine level and glomerular filtration rate (GFR) compared to steroid users. Posttransplant and current spot urinary protein/creatinine rates were also lower in the steroid-free group. However DM, BKVN and induction therapy rates were higher in the steroid-free group. PRA and DSA levels were similar in both groups. On the other hand, posttransplant PRA-I levels were significantly higher in those with less steroid use time. Conclusions:Although steroid free regimens usually worry the clinicians, they can be preferred in patients with low immunological risk for rejection to avoid its side effects such as uncontrolled diabetes, obesity, musculoskeletal problems and cataracts.


REFERENCES

  1. Pascual J. Steroid avoidance or withdrawal in kidney transplantation.Curr Opin Organ Transplant. 2011;16(6):600-5. doi: 10.1097/MOT.0b013e32834c23fa.

  2. Pascual J, Quereda C, Zamora J, Hernández D;Spanish Group for Evidence-Based Medicine in RenalTransplantation. Steroid withdrawal in renal transplantpatients on triple therapy with a calcineurin inhibitor andmycophenolate mofetil: a meta-analysis of randomized,controlled trials. Transplantation. 2004;78(10):1548-56. doi: 10.1097/01.tp.0000140969.43761.1f.

  3. Rostaing L, Cantarovich D, Mourad G, BuddeK, Rigotti P, Mariat C, et al.; CARMEN StudyGroup. Corticosteroid-free immunosuppressionwith tacrolimus, mycophenolate mofetil, anddaclizumab induction in renal transplantation.Transplantation. 2005;79(7):807-14. doi: 10.1097/01.tp.0000154915.20524.0a.

  4. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO,Van Veldhuisen P; Astellas Corticosteroid WithdrawalStudy Group. A prospective, randomized, double-blind,placebo-controlled multicenter trial comparing early (7day) corticosteroid cessation versus long-term, low-dosecorticosteroid therapy. Ann Surg. 2008;248(4):564-77.doi: 10.1097/SLA.0b013e318187d1da.

  5. Vincenti F, Schena FP, Paraskevas S, Hauser IA, WalkerRG, Grinyo J; FREEDOM Study Group. A randomized,multicenter study of steroid avoidance, early steroidwithdrawal or standard steroid therapy in kidneytransplant recipients. Am J Transplant. 2008;8(2):307-16. doi: 10.1111/j.1600-6143.2007.02057.x.

  6. Luan FL, Steffick DE, Ojo AO. Steroid-free maintenanceimmunosuppression in kidney transplantation: is ittime to consider it as a standard therapy? Kidney Int.2009;76(8):825-30. doi: 10.1038/ki.2009.248.

  7. Steiner RW. Steroid-free chronic immunosuppressionin renal transplantation. Curr Opin NephrolHypertens. 2012;21(6):567-73. doi: 10.1097/MNH.0b013e328359226c.

  8. Haller MC, Royuela A, Nagler EV, Pascual J, WebsterAC. Steroid avoidance or withdrawal for kidneytransplant recipients. Cochrane Database Syst Rev.2016;2016(8):CD005632. doi: 10.1002/14651858.CD005632.pub3.

  9. Colvin RB. Antibody-mediated renal allograftrejection: diagnosis and pathogenesis. J Am Soc Nephrol.2007;18(4):1046-56. doi: 10.1681/ASN.2007010073.

  10. Worthington JE, Martin S, Al-Husseini DM, DyerPA, Johnson RW. Posttransplantation production ofdonor HLA-specific antibodies as a predictor of renaltransplant outcome. Transplantation. 2003;75(7):1034-40. doi: 10.1097/01.TP.0000055833.65192.3B.

  11. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, HaischC, et al. Extremely high association between appearanceof HLA antibodies and failure of kidney grafts in a fiveyearlongitudinal study. Am J Transplant. 2007;7(4):864-71. doi: 10.1111/j.1600-6143.2006.01711.x.

  12. Lachmann N, Terasaki PI, Budde K, Liefeldt L, KahlA, Reinke P, et al. Anti-human leukocyte antigenand donor-specific antibodies detected by luminexposttransplant serve as biomarkers for chronic rejectionof renal allografts. Transplantation. 2009;87(10):1505-13. doi: 10.1097/TP.0b013e3181a44206.

  13. Loupy A, Hill GS, Jordan SC. The impact of donorspecificanti-HLA antibodies on late kidney allograftfailure. Nat Rev Nephrol. 2012;8(6):348-57. doi:10.1038/nrneph.2012.81.

  14. Tait BD, Süsal C, Gebel HM, Nickerson PW, ZacharyAA, Claas FH, et al. Consensus guidelines on thetesting and clinical management issues associated withHLA and non-HLA antibodies in transplantation.Transplantation. 2013;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.

  15. Luan FL, Steffick DE, Ojo AO. New-onsetdiabetes mellitus in kidney transplant recipientsdischarged on steroid-free immunosuppression.Transplantation. 2011;91(3):334-41. doi: 10.1097/TP.0b013e318203c25f.

  16. 16.) Pathak V, Madhavan D, Narayanasamy K, Kumar S,Ramalingam V, Sengodagounder B, et al. Low-doserituximab and thymoglobulin induction with steroidfreemaintenance immunosuppression and protocolbiopsies improves long-term patient and graft survivalafter kidney transplantation: survival and safetyoutcomes in more than 1100 patients from a singlecenter. Transplant Direct. 2019;5(8):e475. doi: 10.1097/TXD.0000000000000923.

  17. Sureshkumar KK, Marcus RJ, Chopra B. Role ofsteroid maintenance in sensitized kidney transplantrecipients. World J Transplant. 2015;5(3):102-9. doi:10.5500/wjt.v5.i3.102.

  18. Cozzi E, Biancone L. C1q-binding donor-specificantibody assays help define risk and prognosisin antibody-mediated rejection. Kidney Int.2018;94(4):657-9. doi: 10.1016/j.kint.2018.06.032.

  19. Ponsirenas RVG, Cazarote HB, Araújo SA,Wanderley DC, Shimakura S, Valdameri JS, et al.Anti-HLA donor-specific IgG subclasses and C1qbindingevolution in posttransplant monitoring.Transplant Direct. 2018;4(9):e385. doi: 10.1097/TXD.0000000000000823.

  20. da Silva CK, Meinerz G, Bruno RM, Abud J,Montagner J, Dorsdt DMB, et al. Late impact ofpreformed anti-HLA antibodies on kidney graftoutcome. Transpl Immunol. 2019;55:101212. doi:10.1016/j.trim.2019.06.004.

  21. Thongprayoon C, Hansrivijit P, Leeaphorn N, AcharyaP, Torres-Ortiz A, Kaewput W, et al. Recent advancesand clinical outcomes of kidney transplantation. J ClinMed. 2020;9(4):1193. doi: 10.3390/jcm9041193.




2020     |     www.medigraphic.com